AMGEN Kyprolis
Lack of Assurance of Sterility: Potential cracks in glass vials
1,103 recalls, newest first
Lack of Assurance of Sterility: Potential cracks in glass vials
Defective Delivery System: out of specification result for droplet size distribution at the d90 measurement testing during the 6 month time point..
CGMP Deviations
CGMP Deviations
Marketed without an Approved NDA/ANDA and non-sterility: NANO PNC Water by nebulizer was sampled and found to contain variovorax paradoxus.
Subpotent Drug: out of specification results for assay test.
Failed Dissolution Specifications
cGMP Deviations: Active Pharmaceutical Ingredient (API) manufacturer is on FDA Import Alert.
cGMP Deviations: Active Pharmaceutical Ingredient (API) manufacturer is on FDA Import Alert.
cGMP Deviations: Active Pharmaceutical Ingredient (API) manufacturer is on FDA Import Alert.
cGMP Deviations: Active Pharmaceutical Ingredient (API) manufacturer is on FDA Import Alert.
Marketed without an approved NDA/ANDA: Product contains undeclared sibutramine and desmethylsibutramine.
Subpotent Drug: Out of specification result for pramoxine hydrochloride
Discoloration: there were customer reports of yellow discolored solution. The yellow coloration is the result of oxidation of the amino acid tryptophan due to a damaged overpouch.
Lack of Assurance of Sterility: confirmed customer complaints of leaking bags.
Subpotent Drug
Presence of Foreign Tablets/Capsules; 500 mg capsules were found in bottles labeled to contain 250 mg capsules
Failed Dissolution Specifications
Marketed without an Approved NDA/ANDA; product contains sildenafil and tadalafil which are active pharmaceutical ingredients in FDA approved drugs used to treat erectile dysfunction (ED)
Marketed without an approved NDA/ANDA for which safety and efficacy has not been established.
Subpotent Drug: Out of Specification (OOS) for potency at the 6-month stability time point.
Labeling: Label Mix Up- Incorrect back label applied to the product.
CGMP Deviations
CGMP Deviations